2179.HK

Jiangsu Recbio Technology Co., Ltd. 2179.HK

2179.HK
Jiangsu Recbio Technology Co., Ltd. 2197.HK
Clover Biopharmaceuticals, Ltd. 6996.HK
Antengene Corporation Limited 2487.HK
Cutia Therapeutics 2181.HK
Mabpharm Limited 2511.HK
HighTide Therapeutics Inc 6978.HK
Immunotech Biopharm Ltd 6628.HK
Transcenta Holding Limited 6622.HK
Zhaoke Ophthalmology Limited 1521.HK
Frontage Holdings Corporation

Net profit

EBITDA

P/E Ratio

Capitalization

Performance

Periode 2179.HK 2197.HK 6996.HK 2487.HK 2181.HK 2511.HK 6978.HK 6628.HK 6622.HK 1521.HK
6M -2.13 % 944.78 % 86.17 % 71.05 % 37.50 % 137.80 % -19.33 % 178.69 % 98.06 % -6.72 %
YTD -26.26 % 809.09 % 672.06 % 29.55 % 135.71 % 248.21 % 52.25 % 466.67 % 141.73 % -34.32 %
1Y -20.00 % 536.36 % 525.00 % -30.58 % 83.33 % 264.49 % 74.23 % 233.33 % 137.98 % 91.38 %
3Y -72.48 % 18.64 % 50.43 % -62.05 % 57.14 % -68.50 % -26.84 % -15.42 % 34.06 % -37.64 %
5Y -72.75 % -83.82 % -71.28 % -62.05 % -45.45 % -68.50 % -66.20 % -74.32 % -78.56 % -69.92 %
10Y -72.75 % -83.82 % -71.28 % -62.05 % -45.45 % -68.50 % -78.17 % -74.32 % -78.56 % -66.87 %
From the beginning -72.75 % -83.82 % -71.28 % -62.05 % -45.45 % -68.50 % -78.17 % -74.32 % -78.56 % -66.87 %

Dividend